目的 评价恩格列净治疗2型糖尿病的安全性。方法 检索PubMed、Embase、CENTRAL，中国学术期刊全文数据库（CNKI）、中国生物医学文献数据库（CBM）和万方等数据库，检索时限从建库至2018年3月，纳入有关的随机对照试验（RCTs），用Stata 14软件完成Meta-分析。结果 共纳入10篇文献，6 618例患者。Meta-分析结果发现：治疗末期，恩格列净生殖器感染发生人数明显多于对照组，差异有统计学意义[OR=3.65，95% CI（2.55，5.23）]；恩格列净组尿路感染发生人数与对照组相当，差异无统计学意义[OR=0.95，95% CI（0.82，1.11）]；恩格列净组与对照组低血糖发生人数相当，差异无统计学意义[OR=1.05，95% CI（0.82，1.36）]；恩格列净组与对照组骨折发生人数相当，差异无统计学意义[OR=1.143，95% CI（0.59，2.216）]。结论 恩格列净治疗2型糖尿病仅增加生殖器感染风险，不会增加尿路感染、低血糖、骨折发生率，安全性较好。

Objective To assess the safety of empaliflozin for T2DM patients. Methods Databases including PubMed, Embase, CENTRAL, CBM, CNKI and Wanfang Data were searched to collect randomized controlled trials(RCTs) about safety of empaliflozin for T2DM patients from inception to March 2018, conventional Meta-analysis were performed by Stata 14. Results Ten literature involving 6 618 patients were eligible for Meta-analysis. Meta-analysis showed that at the end of trials, empagliflozin obviously increased the patients of genital infections, the difference was significant[OR=3.65, 95% CI(2.55, 5.23)]; empagliflozin were comparable to control group in the number of patients who had urinary tract infections, hypoglycemia and bone fracture, there were no significant differences[OR=0.95, 95% CI(0.82, 1.11); OR=1.05, 95% CI (0.82, 1.36); OR=1.143, 95% CI (0.59, 2.216)]. Conclusion Empagliflozin only increased the risk of genital infections, excpet for urinary tract infections, hypoglycemia and bone fracture, had good safety.